Cost–utility analysis of MR imaging-guided transurethral ultrasound ablation for the treatment of low- to intermediate-risk localised prostate cancer
All treatment options for 60-year-old men diagnosed with low- to intermediate-risk localised prostate cancer are affected by considerable uncertainty. Accepting high follow-up costs by applying a higher willingness-to-pay, AS is the most favourable treatment option.
Authors
- Dirk Müller (ORCID: https://orcid.org/0000-0002-5576-0192)
- Johannes Rosenbrock (ORCID: https://orcid.org/0000-0003-3340-0556)
- Stephanie Stock (ORCID: https://orcid.org/0000-0002-1726-9300)
- Axel Heidenreich (ORCID: https://orcid.org/0000-0002-2511-3664)
- Julia Simões Corrêa Galendi (ORCID: https://orcid.org/0000-0002-4832-7294)
- Dennis Akuamoa-Boateng (ORCID: https://orcid.org/0000-0002-9355-8470)
- Paul Muhler
Institutions
- Herford Hospital (DE)
- University Hospital Cologne (DE)
- Universidade Estadual Paulista (Unesp) (BR)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-088495
- Citations
- 2
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04